A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome

A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome

Not available.

Saved in:

Bibliographic Details
Main Authors:	Ian M. Bouligny, Guillermo Montalban-Bravo, Koji Sasaki, Naval Daver, Elias Jabbour, Yesid Alvarado, Courtney D. DiNardo, Farhad Ravandi, Gautam Borthakur, Prithviraj Bose, Naveen Pemmaraju, Steven Kornblau, Tapan Kadia, Lucia Masarova, Koichi Takahashi, Michael Andreeff, Alexandre Bazinet, Hui Yang, Rashmi Kanagal-Shamanna, Chitra Hosing, Sherry Pierce, Meghan Meyer, Xuelin Huang, Guillermo Garcia-Manero
Format:	Article
Language:	English
Published:	Ferrata Storti Foundation 2025-02-01
Series:	Haematologica
Online Access:	https://haematologica.org/article/view/11950
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Excellent Response to Nivolumab and Ipilimumab in Metastatic Gastroesophageal Junction Squamous Carcinoma
by: Narayanan Sadagopan, et al.
Published: (2019-01-01)

Ipilimumab- and Nivolumab-Induced Colitis Causing Severe Hypokalemia and QTc Prolongation
by: David Anson, et al.
Published: (2019-01-01)

Re-exposition to ipilimumab plus nivolumab in metastatic Merkel cell carcinoma
by: Valerie Glutsch, et al.
Published: (2024-12-01)

Large‐cell neuroendocrine carcinoma of the kidney effectively treated by nivolumab and ipilimumab
by: Nodoka Okubo, et al.
Published: (2025-03-01)

Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
by: Drew M Pardoll, et al.
Published: (2020-10-01)

Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience
by: Vidhya Karivedu, et al.
Published: (2019-01-01)

Colitis grave inmunomediada por Nivolumab-Ipilimumab: a propósito de un caso
by: Maria Victoria Foglino, et al.
Published: (2025-07-01)

Corrigendum to “Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience”
by: Vidhya Karivedu, et al.
Published: (2019-01-01)

Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab
by: Razelle Kurzrock, et al.
Published: (2022-12-01)

Disproportionality analysis of adverse events associated with ipilimumab and nivolumab combination therapy based on FAERS database
by: Xianyu Dai, et al.
Published: (2025-07-01)

Correction: Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
Published: (2020-10-01)

Circulating cytokine associations with clinical outcomes in melanoma patients treated with combination nivolumab plus ipilimumab
by: Jiajia Chen, et al.
Published: (2025-12-01)

Efficacy and safety of nivolumab plus ipilimumab in gastrointestinal cancers: a systematic review and meta-analysis
by: Bowen Dai, et al.
Published: (2025-01-01)

Immune-related hepatitis and hypophysitis are associated with superior survival in melanoma patients treated with combined ipilimumab and nivolumab
by: Hifaa Al Remawi, et al.
Published: (2025-12-01)

Physiologically Based Pharmacokinetic Models for Infliximab, Ipilimumab, and Nivolumab Developed with GastroPlus to Predict Hepatic Concentrations
by: Celeste Vallejo, et al.
Published: (2025-03-01)

A Case of PMR‐Like irAE Developing After Treatment With Ipilimumab and Nivolumab for Lung Cancer
by: Ryuichi Utsumi, et al.
Published: (2025-06-01)

Organ‐Specific Responses to Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma: A Multicenter, Retrospective Study
by: Jung Sun Kim, et al.
Published: (2025-06-01)

Enhanced efficacy of ipilimumab plus nivolumab in angiogenic subtypes of metastatic clear-cell renal cell carcinoma
by: Xiaofan Lu, et al.
Published: (2025-05-01)

First-line Nivolumab plus Ipilimumab in patients with advanced melanoma previously treated with adjuvant systemic therapy
by: K. Kisielewska, et al.
Published: (2024-01-01)

Nivolumab and ipilimumab therapy in a patient with non-small cell lung cancer with chronic kidney disease
by: Hiroaki Satoh, et al.
Published: (2022-06-01)

Retreatment With Nivolumab and Ipilimumab in Pleural Mesothelioma Following Disease Progression After a Durable Response: Case Series
by: Illaa Smesseim, MD, et al.
Published: (2025-07-01)

Cytokine release syndrome treated with tocilizumab following ipilimumab–nivolumab combination therapy in advanced renal cell carcinoma
by: Toru Inoue, et al.
Published: (2025-01-01)

A phase II study of nivolumab, ipilimumab, and radiation in combination with influenza vaccine in patients with pancreatic cancer (INFLUENCE)
by: I.M. Chen, et al.
Published: (2025-06-01)

Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma
by: Jin Yao, et al.
Published: (2022-03-01)

Neoadjuvant ipilimumab plus nivolumab in locally advanced melanoma: A real-world single-centre retrospective study
by: Patrick Schummer, et al.
Published: (2023-01-01)

Comparative safety of nivolumab plus ipilimumab versus nivolumab plus relatlimab in advanced melanoma: a pharmacovigilance study based on the FDA adverse event reporting system (FAERS)
by: Shanshan Xu, et al.
Published: (2025-07-01)

A durable complete response resulting from treatment with nivolumab plus ipilimumab for metastatic collecting duct carcinoma of the kidney
by: Keisuke Funajima, et al.
Published: (2023-07-01)

Early detection of myocarditis caused by immune checkpoint inhibitor therapy with nivolumab and ipilimumab for advanced recurrent renal cell carcinoma
by: Maki Todo, et al.
Published: (2025-02-01)

Hypercalcemia as an Immune-Related Adverse Event in a Patient Receiving Nivolumab and Ipilimumab for Metastatic Melanoma: A Case Report
by: Sam Plessers, et al.
Published: (2025-01-01)

Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain–Barré Syndrome
by: Alessio Cortellini, et al.
Published: (2018-01-01)

Effectiveness and safety of nivolumab and ipilimumab in older adults with renal cell carcinoma: findings from a multicenter observational study in Poland
by: Artur Drobniak, et al.
Published: (2025-08-01)

Neutrophil to lymphocyte ratio and tumour burden for treatment efficacy stratification in renal cell carcinoma patients receiving nivolumab plus ipilimumab
by: M. Oshima, et al.
Published: (2025-03-01)

Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trial
by: Pavlos Msaouel, et al.
Published: (2025-01-01)

Phase I/II study of BMS-986156 with ipilimumab or nivolumab with or without stereotactic ablative radiotherapy in patients with advanced solid malignancies
by: Wei Li, et al.
Published: (2024-10-01)

Neoadjuvant immunotherapy with ipilimumab/nivolumab induces a complete response of a primary malignant melanoma in an 89 years old patient
by: Pascal Spahn, et al.
Published: (2024-12-01)

Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study
by: Tanja D de Gruijl, et al.
Published: (2024-09-01)

Efficacy and prognostic factors of anti-PD1 and nivolumab-ipilimumab therapy in advanced melanoma patients resistant to prior ICI treatment
by: Caner Acar, et al.
Published: (2024-12-01)

Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment
by: Sabine Schmid, MD, et al.
Published: (2024-12-01)

Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)
by: Michael Hurwitz, et al.
Published: (2024-04-01)

Sarcomatoid diffuse pleural mesothelioma in an 80-year-Old woman with long-term response to nivolumab plus ipilimumab: A case report
by: Yukiko Yoshida, et al.
Published: (2025-01-01)